|Bid||5.82 x 1000|
|Ask||6.22 x 800|
|Day's Range||5.81 - 6.29|
|52 Week Range||3.01 - 17.50|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for APYX
If you want to know who really controls Apyx Medical Corporation ( NASDAQ:APYX ), then you'll have to look at the...
Apyx Medical Corporation (NASDAQ: APYX) has FDA received 510(k) clearance for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures to treat moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II, or III. The company expects to begin a limited launch of Renuvion for this indication in Q3 of 2022, to enter full commercialization by the end of 2022. "We a
The last three months have been tough on Apyx Medical Corporation ( NASDAQ:APYX ) shareholders, who have seen the share...